FEMYNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
FEMASYS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.63−0.02 (-1.21%)
Close on Oct 19, 2026
- Market cap
- $5.47M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
24.7%
2M of 8M shares
Institutional holders
17
17 new, 0 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
5 buys · 0 sales
Net bought $134.00K
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Nantahala Capital Partners Limited Partnership | 803,038 | 9.99% | 13D (active) | Aug 10, 2026 |
| Stonepine Capital Management, LLC | 625,000 | 7.20% | 13G (passive) | Aug 10, 2026 |
| PharmaCyte Biotech, Inc. | 4,932,825 | 7.87% | 13G (passive) | Mar 17, 2026 |
| Alumni Capital GP LLC | 4,773,579 | 9.99% | 13G (passive) | Sep 4, 2025 |
| Rosalind Master Fund L.P. | 4,687,500 | 9.90% | 13G (passive) | Aug 10, 2026 |
| Ryan M. Lane | 468,750 | 5.60% | 13G (passive) | Sep 30, 2026 |
| Dauntless Investment Group, LLC | 4,395,996 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Chernett Jorey | 3,034,335 | 9.30% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of FEMY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Dauntless Investment Group, LLC | 1,867,987 | 22.30% | $7.81M | New | 6.13% |
| Vanguard Capital Management LLC | 62,232 | 0.74% | $260.13K | New | 0.00% |
| Jane Street Group, LLC | 52,511 | 0.63% | $219.50K | New | 0.00% |
| Geode Capital Management, LLC | 30,920 | 0.37% | $129.25K | New | 0.00% |
| UBS Group AG | 18,777 | 0.22% | $78.49K | New | 0.00% |
| Citadel Advisors LLC | 16,921 | 0.20% | $70.73K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 12,492 | 0.15% | $52.22K | New | 0.00% |
| Osaic Holdings, Inc. | 2,397 | 0.03% | $10.02K | New | 0.00% |
| BlackRock, Inc. | 1,784 | 0.02% | $7.46K | New | 0.00% |
| Northwestern Mutual Wealth Management Co | 1,000 | 0.01% | $4.18K | New | 0.00% |
| SRS Capital Advisors, Inc. | 900 | 0.01% | $3.76K | New | 0.00% |
| Whittier Trust Co Of Nevada Inc | 794 | 0.01% | $3.07K | New | 0.00% |
| Trust Co Of Toledo NA /Oh/ | 87 | 0.00% | $364 | New | 0.00% |
| IFP Advisors, Inc | 50 | 0.00% | $209 | New | 0.00% |
| Barclays PLC | 8 | 0.00% | $33 | New | 0.00% |
| SBI Securities Co., Ltd. | 7 | 0.00% | $29 | New | 0.00% |
| Morgan Stanley | 3 | 0.00% | $13 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 17 | 2M | 24.7% | 17 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of FEMY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 34,296 | 0.41% | $143.36K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 27,936 | 0.33% | $116.77K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -465 | -0.01% | -$1.94K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kathy Lee-Sepsick | Chief Executive Officer, Director | 87,848 | 1.05% | Aug 11, 2026 |
| Dov Elefant | Chief Financial Officer | 15,625 | 0.19% | Aug 11, 2026 |
| Jeffrey Gerald Mifek | Chief Clinical-Medical Affairs | 1,411 | 0.02% | Aug 11, 2026 |
| John Charles Canning | Chief Operating Officer | 4,375 | 0.05% | Aug 11, 2026 |
| Jeremy Alexander Sipos | Chief Technology Officer | 3,125 | 0.04% | Aug 11, 2026 |
| Kelley Stinson Nicholas | Chief Commercial Officer | 125 | 0.00% | Jul 1, 2025 |
| Daniel Scott Currie | Chief Operating Officer | 109,240 | 1.30% | Jun 4, 2025 |
| Christine E. Thomas | Chief Reg & Clinical Officer | – | – | Jan 30, 2025 |
| Kenneth D. Eichenbaum | Director | 25,010 | 0.30% | Aug 11, 2026 |
| Charles Larsen | Director | 56 | 0.00% | Aug 11, 2026 |
| Edward R. Uzialko | Director | 1,217,406 | 14.54% | Aug 11, 2026 |
| Alistair Milnes | Director | – | – | Aug 11, 2026 |
| Joshua Silverman | Director | – | – | Mar 18, 2026 |
| PharmaCyte Biotech, Inc. | 10% owner | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Dov Elefant Chief Financial Officer | Aug 7, 2026 | Buy | +15,625 | $3.20 | $50.00K | 15,625 |
| Jeffrey Gerald Mifek Chief Clinical-Medical Affairs | Aug 7, 2026 | Buy | +3,125 | $3.20 | $10.00K | 3,125 |
| Jeremy Alexander Sipos Chief Technology Officer | Aug 7, 2026 | Buy | +3,125 | $3.20 | $10.00K | 3,125 |
| Kathy Lee-Sepsick Chief Executive Officer, Director | Aug 7, 2026 | Buy | +15,625 | $3.20 | $50.00K | 15,625 |
| John Charles Canning Chief Operating Officer | Aug 7, 2026 | Buy | +4,375 | $3.20 | $14.00K | 4,375 |
| Dov Elefant Chief Financial Officer | Aug 27, 2025 | Discretionary | +38,828 | – | – | 58,436 |
| Kathy Lee-Sepsick Chief Executive Officer, Director | Aug 27, 2025 | Discretionary | +48,535 | – | – | 360,627 |
| Charles Larsen Director | Jun 2, 2025 | Discretionary | +24,510 | $1.02 | $25.00K | 56 |
| Dov Elefant Chief Financial Officer | Jun 2, 2025 | Discretionary | +19,608 | $1.02 | $20.00K | 19,608 |
| Kathy Lee-Sepsick Chief Executive Officer, Director | Jun 2, 2025 | Discretionary | +34,314 | $1.02 | $35.00K | 312,092 |
| Daniel Scott Currie Chief Operating Officer | Jun 2, 2025 | Discretionary | +19,608 | $1.02 | $20.00K | 86,275 |
| William Benson Witte Director | Dec 15, 2021 | Other | +12,191 | – | – | 12,191 |
| John Dyett Director | Dec 15, 2021 | Other | −3,219,795 | – | – | 0 |
| John Dyett Director | Dec 15, 2021 | Other | +175,635 | – | – | 290,344 |
| John Dyett Director, 10% owner | Jun 23, 2021 | Buy | +1,000 | $9.95 | $9.95K | 114,709 |
| John Dyett Director, 10% owner | Jun 22, 2021 | Conversion | +63,709 | – | – | 113,709 |
| John Dyett Director, 10% owner | Jun 22, 2021 | Buy | +40,000 | $13.00 | $520.00K | 50,000 |
| John Dyett Director, 10% owner | Jun 22, 2021 | Conversion | +2,271,453 | – | – | 3,219,795 |
| John Dyett Director, 10% owner | Jun 22, 2021 | Conversion | +948,342 | – | – | 948,342 |
| John Q. Adams JR Director | Jun 22, 2021 | Conversion | +91,245 | – | – | 131,245 |
| John Q. Adams JR Director | Jun 22, 2021 | Conversion | +108,693 | – | – | 239,938 |
| John Q. Adams JR Director | Jun 22, 2021 | Buy | +40,000 | $13.00 | $520.00K | 40,000 |
| Edward R. Uzialko Director | Jun 22, 2021 | Conversion | +1,059,445 | – | – | 1,187,231 |
| Edward R. Uzialko Director | Jun 22, 2021 | Conversion | +30,175 | – | – | 30,175 |
| Edward R. Uzialko Director | Jun 22, 2021 | Buy | +100,000 | $13.00 | $1.30M | 127,786 |
| Charles Larsen Director | Jun 22, 2021 | Conversion | +10,587 | – | – | 17,587 |
| Charles Larsen Director | Jun 22, 2021 | Buy | +7,000 | $13.00 | $91.00K | 7,000 |
| John Dyett Director, 10% owner | Jun 18, 2021 | Buy | +10,000 | $12.88 | $128.80K | 10,000 |
| John Dyett Director, 10% owner | Jun 18, 2021 | Buy | +2,500 | $13.18 | $32.95K | 2,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.